Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

524 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
Paul F, Marignier R, Palace J, Arrambide G, Asgari N, Bennett JL, Cree BAC, De Sèze J, Fujihara K, Kim HJ, Hornby R, Huda S, Kissani N, Kleiter I, Kuwabara S, Lana-Peixoto M, Law L, Leite MI, Pandit L, Pittock SJ, Quan C, Ramanathan S, Rotstein D, Saiz A, Sato DK, Vaknin-Dembinsky A. Paul F, et al. Among authors: de seze j. Neurol Neuroimmunol Neuroinflamm. 2023 May 31;10(4):e200124. doi: 10.1212/NXI.0000000000200124. Print 2023 Jul. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37258412 Free PMC article.
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis.
Garcia A, Dugast E, Shah S, Morille J, Lebrun-Frenay C, Thouvenot E, De Sèze J, Le Page E, Vukusic S, Maurousset A, Berger E, Casez O, Labauge P, Ruet A, Raposo C, Bakdache F, Buffels R, Le Frère F, Nicot A, Wiertlewski S, Gourraud PA, Berthelot L, Laplaud D. Garcia A, et al. Among authors: de seze j. Neurol Neuroimmunol Neuroinflamm. 2023 Feb 21;10(3):e200091. doi: 10.1212/NXI.0000000000200091. Print 2023 May. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 36810163 Free PMC article.
Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
Pittock SJ, Barnett M, Bennett JL, Berthele A, de Sèze J, Levy M, Nakashima I, Oreja-Guevara C, Palace J, Paul F, Pozzilli C, Yountz M, Allen K, Mashhoon Y, Kim HJ. Pittock SJ, et al. Among authors: de seze j. Ann Neurol. 2023 Jun;93(6):1053-1068. doi: 10.1002/ana.26626. Epub 2023 Apr 5. Ann Neurol. 2023. PMID: 36866852
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France.
Sormani MP, Salvetti M, Labauge P, Schiavetti I, Zephir H, Carmisciano L, Bensa C, De Rossi N, Pelletier J, Cordioli C, Vukusic S, Moiola L, Kerschen P, Radaelli M, Théaudin M, Immovilli P, Casez O, Capobianco M, Ciron J, Trojano M, Stankoff B, Créange A, Tedeschi G, Clavelou P, Comi G, Thouvenot E, Battaglia MA, Moreau T, Patti F, De Sèze J, Louapre C; Musc-19; Covisep study groups. Sormani MP, et al. Among authors: de seze j, de rossi n. Ann Clin Transl Neurol. 2021 Aug;8(8):1738-1744. doi: 10.1002/acn3.51408. Epub 2021 Jul 7. Ann Clin Transl Neurol. 2021. PMID: 34240579 Free PMC article.
The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus.
De Sèze J, Suchet L, Mekies C, Manchon E, Labauge P, Guennoc AM, Defer G, Clavelou P, Castelnovo G, Bourre B, Bensa-Koscher C, Al Khedr A, Le Mao J, Villemur L, Bouée S, Luciani L, Vermersch P. De Sèze J, et al. Neurol Ther. 2023 Apr;12(2):351-369. doi: 10.1007/s40120-022-00430-z. Epub 2022 Dec 24. Neurol Ther. 2023. PMID: 36564664 Free PMC article. Review.
Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study.
Moreau A, Kolitsi I, Kremer L, Fleury M, Lanotte L, Sellal F, Gaultier C, Ahle G, Courtois S, Fickl A, Mostoufizadeh S, Dentel C, Collongues N, de Seze J, Bigaut K. Moreau A, et al. Among authors: de seze j. Mult Scler Relat Disord. 2023 Nov;79:104942. doi: 10.1016/j.msard.2023.104942. Epub 2023 Aug 13. Mult Scler Relat Disord. 2023. PMID: 37633034
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study.
Querol L, De Sèze J, Dysgaard T, Levine T, Rao TH, Rivner M, Hartung HP, Kiessling P, Shimizu S, Marmol D, Bozorg A, Colson AO, Massow U, Eftimov F; CIDP01 Study Investigators. Querol L, et al. Among authors: de seze j. J Neurol Neurosurg Psychiatry. 2024 May 10:jnnp-2023-333112. doi: 10.1136/jnnp-2023-333112. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 38729747 Free article.
Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
Fox RJ, Cree BAC, de Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Singh CM, Altincatal A, Belviso N, Avila RL, Ho PR, Su R, Engle R, Sangurdekar D, de Moor C, Fisher E, Kieseier BC, Rudick RA. Fox RJ, et al. Among authors: de seze j. Neurology. 2024 May 14;102(9):e209357. doi: 10.1212/WNL.0000000000209357. Epub 2024 Apr 22. Neurology. 2024. PMID: 38648580 Clinical Trial.
524 results